BioMedica |

Original Article

VOLUME: 36 | ISSUE: 2 | Jun 30, 2020 | PAGE: (171 - 176) | DOI: 10.24911/BioMedica/5-132

Analysis of Serial C-Reactive Protein Levels in Critically Ill COVID-19 Patients Receiving Tocilizumab

Authors: Atika Masood , Omair Farooq , Sadaf Waris , Muhammad Khan , Asim Mumtaz , Maleeha Aslam , Muhammad Usama

Article Info

Authors

Atika Masood

Akhtar Saeed Medical and Dental College, Lahore – Pakistan.

Omair Farooq

Farooq Hospital West Wood, Lahore– Pakistan.

Sadaf Waris

Akhtar Saeed Medical and Dental College, Lahore – Pakistan.

Muhammad Khan

Farooq Hospital West Wood, Lahore– Pakistan.

Asim Mumtaz

Farooq Hospital West Wood, Lahore– Pakistan.

Maleeha Aslam

Akhtar Saeed Medical and Dental College, Lahore – Pakistan.

Muhammad Usama

Farooq Hospital West Wood, Lahore– Pakistan.

Publication History

Received: May 28, 2020

Revised: June 15, 2020

Accepted: June 24, 2020

Published: June 30, 2020

Abstract

Background and Objective: COVID-19 can cause severe acute respiratory distress syndrome. With deteriorating disease, most of the patients may require intensive care admission. This study was carried out to determine and evaluate the response of Tocilizumab with special reference to C-reactive protein (CRP) in critically ill patients presented to Farooq Hospital, West Wood Lahore.
Methods: This retrospective study included the data of 55 critically ill COVID-19 patients (respiratory rate ≥30, SpO2<93%, oxygen requirement ≥5L/min, PaO2/FiO2 ≤300 mmHg) admitted in Corona unit of Farooq Hospital West Wood Lahore, who were being treated with Tocilizumab alongwith standard treatment protocol between April 27 and June 21, 2020. The data has been retrieved from hospital records after taking appropriate permission and consent. Demographic, clinical features and serum CRP were recorded for each of them, before and after administration of Tocilizumab. Data analysis was done by Statistical Package for the Social Sciences (SPSS) version 22.0 and expressed as frequency and percentages.
Results: Out of 55 patients who were administered Tocilizumab, 72.7% survived whereas 27.3% died. There was higher median reduction of CRP levels in patients who survived (77.5 to 34.9 mg/L) as compared to those who died (65.5 to 45.3 mg/L). There was a statistically significant difference between CRP levels at the time of admission, 72 hours after Tocilizumab was administered (P<0.0001).
Conclusion: Tocilizumab administration might be helpful in reducing the complications of cytokine storm in patients with severe COVID-19 pneumonia.

Keywords: C-reactive protein, Pneumonia, COVID-19, Tocilizumab, Critically ill.

Pubmed Style

Atika Masood, Omair Farooq, Sadaf Waris, Muhammad Khan, Asim Mumtaz, Maleeha Aslam, Muhammad Usama. Analysis of Serial C-Reactive Protein Levels in Critically Ill COVID-19 Patients Receiving Tocilizumab. BioMedica. 2020; 30 (June 2020): 171-176. doi:10.24911/BioMedica/5-132

Web Style

Atika Masood, Omair Farooq, Sadaf Waris, Muhammad Khan, Asim Mumtaz, Maleeha Aslam, Muhammad Usama. Analysis of Serial C-Reactive Protein Levels in Critically Ill COVID-19 Patients Receiving Tocilizumab. https://biomedicapk.com/articles/online_first/132 [Access: May 07, 2024]. doi:10.24911/BioMedica/5-132

AMA (American Medical Association) Style

Vancouver/ICMJE Style

Atika Masood, Omair Farooq, Sadaf Waris, Muhammad Khan, Asim Mumtaz, Maleeha Aslam, Muhammad Usama. Analysis of Serial C-Reactive Protein Levels in Critically Ill COVID-19 Patients Receiving Tocilizumab. BioMedica. (2020), [cited May 07, 2024]; 30 (June 2020): 171-176. doi:10.24911/BioMedica/5-132

Harvard Style

Atika Masood, Omair Farooq, Sadaf Waris, Muhammad Khan, Asim Mumtaz, Maleeha Aslam, Muhammad Usama (2020) Analysis of Serial C-Reactive Protein Levels in Critically Ill COVID-19 Patients Receiving Tocilizumab. BioMedica, 30 (June 2020): 171-176. doi:10.24911/BioMedica/5-132

Chicago Style

Atika Masood, Omair Farooq, Sadaf Waris, Muhammad Khan, Asim Mumtaz, Maleeha Aslam, Muhammad Usama. "Analysis of Serial C-Reactive Protein Levels in Critically Ill COVID-19 Patients Receiving Tocilizumab." 30 (2020), 171-176. doi:10.24911/BioMedica/5-132

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Atika Masood, Omair Farooq, Sadaf Waris, Muhammad Khan, Asim Mumtaz, Maleeha Aslam, Muhammad Usama (2020) Analysis of Serial C-Reactive Protein Levels in Critically Ill COVID-19 Patients Receiving Tocilizumab. , 30 (June 2020), 171-176. doi:10.24911/BioMedica/5-132